Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi & Co. Ltd.

www.shionogi.co.jp

Latest From Shionogi & Co. Ltd.

Janssen And ViiV: Giving HIV/AIDS Patients Options Is Key

With EU submissions for once-monthly long-acting  anti-HIV antivirals in hand, Janssen and ViiV appear to have set their sights on providing patients with more options.

Infectious Diseases Research and Development Strategies

Novartis’s Zolgensma Loses EU Accelerated Assessment

Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.

Europe Drug Review

UK's AMRC Licenses Shionogi Superbug Therapy

As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.

Infectious Diseases Companies

EU Accelerated Assessment – Hard To Get, Hard To Keep

It’s hard enough in the first place for companies to persuade the European Medicines Agency that their planned marketing authorization application should be fast-tracked. Many are also finding that after accelerated assessment is granted, it is taken away during the actual review.

Review Pathway Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Company Type
  • Top Japanese Pharma
  • Parent & Subsidiaries
  • Shionogi & Co. Ltd.
  • Senior Management
  • Isao Teshirogi, PhD, Pres. & CEO
  • Contact Info
  • Shionogi & Co. Ltd.
    Phone: (81) 6 6202 2161
    1-8, Doshomachi 3-chome
    Chuo-ku
    Osaka, 541 0045
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register